Literature DB >> 21402764

Type I interferons increase host susceptibility to Trypanosoma cruzi infection.

Anne-Danielle C Chessler1, Kacey L Caradonna, Akram Da'dara, Barbara A Burleigh.   

Abstract

Trypanosoma cruzi, the protozoan parasite that causes human Chagas' disease, induces a type I interferon (IFN) (IFN-α/β) response during acute experimental infection in mice and in isolated primary cell types. To examine the potential impact of the type I IFN response in shaping outcomes in experimental T. cruzi infection, groups of wild-type (WT) and type I IFN receptor-deficient (IFNAR(-/-)) 129sv/ev mice were infected with two different T. cruzi strains under lethal and sublethal conditions and several parameters were measured during the acute stage of infection. The results demonstrate that type I IFNs are not required for early host protection against T. cruzi. In contrast, under conditions of lethal T. cruzi challenge, WT mice succumbed to infection whereas IFNAR(-/-) mice were ultimately able to control parasite growth and survive. T. cruzi clearance in and survival of IFNAR(-/-) mice were accompanied by higher levels of IFN-γ production by isolated splenocytes in response to parasite antigen. The suppression of IFN-γ in splenocytes from WT mice was independent of IL-10 levels. While the impact of type I IFNs on the production of IFN-γ and other cytokines/chemokines remains to be fully determined in the context of T. cruzi infection, our data suggest that, under conditions of high parasite burden, type I IFNs negatively impact IFN-γ production, initiating a detrimental cycle that contributes to the ultimate failure to control infection. These findings are consistent with a growing theme in the microbial pathogenesis field in which type I IFNs can be detrimental to the host in a variety of nonviral pathogen infection models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402764      PMCID: PMC3088151          DOI: 10.1128/IAI.01176-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  56 in total

1.  Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection.

Authors:  V Michailowsky; N M Silva; C D Rocha; L Q Vieira; J Lannes-Vieira; R T Gazzinelli
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

2.  Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling.

Authors:  Diana L Martin; Kaja Murali-Krishna; Rick L Tarleton
Journal:  Infect Immun       Date:  2010-05-10       Impact factor: 3.441

3.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta.

Authors:  C Manca; L Tsenova; A Bergtold; S Freeman; M Tovey; J M Musser; C E Barry; V H Freedman; G Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

4.  Immediate/early response to Trypanosoma cruzi infection involves minimal modulation of host cell transcription.

Authors:  Silvia Vaena de Avalos; Ira J Blader; Michael Fisher; John C Boothroyd; Barbara A Burleigh
Journal:  J Biol Chem       Date:  2001-10-19       Impact factor: 5.157

5.  Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection.

Authors:  Khuong B Nguyen; Thais P Salazar-Mather; Marc Y Dalod; Jeffrey B Van Deusen; Xiao-qing Wei; Foo Y Liew; Michael A Caligiuri; Joan E Durbin; Christine A Biron
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

6.  Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox.

Authors:  K B Nguyen; L P Cousens; L A Doughty; G C Pien; J E Durbin; C A Biron
Journal:  Nat Immunol       Date:  2000-07       Impact factor: 25.606

7.  Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways.

Authors:  Lene Malmgaard; Thais P Salazar-Mather; Casey A Lewis; Christine A Biron
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Distinct requirements for IFNs and STAT1 in NK cell function.

Authors:  C K Lee; D T Rao; R Gertner; R Gimeno; A B Frey; D E Levy
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

9.  Role of IFN-alpha/beta and IL-12 in the activation of natural killer cells and interferon-gamma production during experimental infection with Trypanosoma cruzi.

Authors:  C Une; J Andersson; A Orn
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

10.  Mycobacterium bovis bacillus Calmette-Guérin infection promotes SOCS induction and inhibits IFN-gamma-stimulated JAK/STAT signaling in J774 macrophages.

Authors:  Kenichi Imai; Tomoko Kurita-Ochiai; Kuniyasu Ochiai
Journal:  FEMS Immunol Med Microbiol       Date:  2003-11-28
View more
  17 in total

1.  Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock.

Authors:  Penny A Rudd; Jane Wilson; Joy Gardner; Thibaut Larcher; Candice Babarit; Thuy T Le; Itaru Anraku; Yutaro Kumagai; Yueh-Ming Loo; Michael Gale; Shizuo Akira; Alexander A Khromykh; Andreas Suhrbier
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

2.  IRF3 inhibits IFN-γ-mediated restriction of intracellular pathogens in macrophages independently of IFNAR.

Authors:  Karolina Maciag; Raktima Raychowdhury; Karen Smith; Alexis M Schneider; Jörn Coers; Maxwell R Mumbach; Schraga Schwartz; Nir Hacohen
Journal:  J Leukoc Biol       Date:  2021-11-26       Impact factor: 6.011

3.  Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Authors:  Matteo Rossi; Patrik Castiglioni; Mary-Anne Hartley; Remzi Onur Eren; Florence Prével; Chantal Desponds; Daniel T Utzschneider; Dietmar Zehn; Maria G Cusi; F Matthew Kuhlmann; Stephen M Beverley; Catherine Ronet; Nicolas Fasel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 4.  Type I interferons in infectious disease.

Authors:  Finlay McNab; Katrin Mayer-Barber; Alan Sher; Andreas Wack; Anne O'Garra
Journal:  Nat Rev Immunol       Date:  2015-02       Impact factor: 53.106

Review 5.  Impact of Type I Interferons on Susceptibility to Bacterial Pathogens.

Authors:  Adeline Peignier; Dane Parker
Journal:  Trends Microbiol       Date:  2021-02-02       Impact factor: 18.230

6.  Pathogenic potential of interferon αβ in acute influenza infection.

Authors:  Sophia Davidson; Stefania Crotta; Teresa M McCabe; Andreas Wack
Journal:  Nat Commun       Date:  2014-05-21       Impact factor: 14.919

Review 7.  The Regulation of CD4(+) T Cell Responses during Protozoan Infections.

Authors:  Christian R Engwerda; Susanna S Ng; Patrick T Bunn
Journal:  Front Immunol       Date:  2014-10-13       Impact factor: 7.561

8.  Opposing roles for interferon regulatory factor-3 (IRF-3) and type I interferon signaling during plague.

Authors:  Ami A Patel; Hanni Lee-Lewis; Jennifer Hughes-Hanks; Craig A Lewis; Deborah M Anderson
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

9.  The use of a heterogeneously controlled mouse population reveals a significant correlation of acute phase parasitemia with mortality in Chagas disease.

Authors:  Tiago L M Sanches; Larissa D Cunha; Grace K Silva; Paulo M M Guedes; João Santana Silva; Dario S Zamboni
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

10.  Transcriptional analysis of murine macrophages infected with different Toxoplasma strains identifies novel regulation of host signaling pathways.

Authors:  Mariane B Melo; Quynh P Nguyen; Cynthia Cordeiro; Musa A Hassan; Ninghan Yang; Renée McKell; Emily E Rosowski; Lindsay Julien; Vincent Butty; Marie-Laure Dardé; Daniel Ajzenberg; Katherine Fitzgerald; Lucy H Young; Jeroen P J Saeij
Journal:  PLoS Pathog       Date:  2013-12-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.